Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • LRRK2 Challenge, 2014
    Inhibition of PKA as a Mechanism to Reverse LRRK2 Mutation-induced Parkinson's Disease

    Study Rationale:
    Unraveling the role of LRRK2 mutations in disease remains a critical question in Parkinson’s research. The high expression of LRRK2 protein in part of the brain called the striatum...

  • Target Validation, 2014
    5-alpha-reductase Inhibition for the Treatment of Levodopa-induced Dyskinesia

    Study Rationale:
    Although the cause of levodopa-induced dyskinesia is still unclear, these motor complications appear to be due to abnormal dopamine transmission in the brain. Compelling evidence has...

  • Research Grant, 2014
    Evaluation of mGlu4 Positive Allosteric Modulators in Models of Parkinson’s Disease

    Study Rationale:                   
    Levodopa and other available treatments for Parkinson’s disease (PD) are initially effective but have unpredictable therapeutic effects and induce serious adverse...

  • Therapeutic Pipeline Program, 2014
    Liver X Receptor Agonists as Novel Therapeutics for Parkinson’s Disease

    Study Rationale:                   
    Inflammation is an early and characteristic feature of Parkinson’s disease. Recent studies connect a protein called the liver X receptor (LXR) to inflammation in key...

  • Target Validation, 2014
    Dual GluK1/GluK3 Antagonism as a Neuroprotective Target

    Objective/Rationale:             
    Over activation of glutamate receptors may contribute to the loss of dopamine cells in Parkinson’s disease (PD). Research suggests that drugs that target these...

  • Rapid Response Innovation Awards, 2014
    Neuroimaging Carriers of the Alpha-synuclein E46K Mutation as a Model of Idiopathic Lewy Body Disease

    Study Rationale:
    In 2004 our group described, for the first time in literature, the E46K mutation of the alpha-synuclein gene in a family from the Basque region of Spain. The rare E46K mutation is...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.